asco.org3d
T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A systematic review and meta-analysis.
NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.
asco.org6d
For PR Professionals
This page contains important information for corporate and institutional public relations professionals about ASCO Meetings. Once an abstract is submitted to an ASCO Meeting, the abstract and study ...
asco.org5d
Conflict of Interest (COI)
The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...
asco.org6d
Funding Opportunities
Our grants and awards support basic, translational and clinical cancer research done by gifted physician-scientists at every stage of their careers, from the best and brightest among young ...
asco.org4d
ASCO's Advocacy Toolkit
The Association for Clinical Oncology (ASCO) offers multiple ways for you and your colleagues to engage with policymakers and educate them on ASCO’s advocacy priorities, while leveraging your insights ...
asco.org3d
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
Career Development
ASCO is committed to providing members with lifelong learning and training opportunities through an array of Professional Development programs and activities. ASCO’s distinct leadership programs are ...
asco.org4d
Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy.
83.3% (n=25) vs 6.7% (n=2) vs 10% (n=3) 21.8% (n=8) vs 15.6% (n=2) vs 59.3% (n=19) 44.4% (n=4) vs 11.1% (n=1) vs 44.4% (n=4) <0.001 ...
asco.org3d
Feasibility of pharmacist co-management for patients prescribed oral anticancer therapy for gastrointestinal cancers.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Combination immunotherapy selection for non-PD-1 axis driven tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5d
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...